Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer (Q35913214)
Jump to navigation
Jump to search
scientific article published on 30 March 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer |
scientific article published on 30 March 2012 |
Statements
1 reference
Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer (English)
1 reference
Miguel MartÃn
1 reference
Anatoly Makhson
1 reference
Joseph Gligorov
1 reference
Mikhail Lichinitser
1 reference
Ana Lluch
1 reference
Vladimir Semiglazov
1 reference
Nana Scotto
1 reference
Lada Mitchell
1 reference
Sergei Tjulandin
1 reference
1 reference
Identifiers
1 reference